Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages
Sign Up to like & getrecommendations! Published in 2018 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfx319
Abstract: Background Fabry patients on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in estimated glomerular filtration rate (eGFR) and an increase of the Mainz Severity Score Index. Methods In this prospective… read more here.
Keywords: switch agalsidase; group; agalsidase; agalsidase beta ... See more keywords